Results 171 to 180 of about 112,037 (251)
Fulminant disseminated histoplasmosis in a pediatric patient with ataxia-telangiectasia and autoimmune hepatitis: A diagnostic and therapeutic challenge. [PDF]
Loredo Paz LE +4 more
europepmc +1 more source
Charting the course of Sjögren's disease: A historical analysis of scientific progress
Abstract Sjögren's disease (SjD) bears the name of the Swedish ophthalmologist Henrik Sjögren. His 1933 doctoral thesis on keratoconjunctivitis sicca ignited interest, yet much remains under debate. SjD is an autoimmune disorder that primarily affects the exocrine glands, particularly the salivary and lacrimal glands, leading to a dryness of the eyes ...
Diego Ustárroz Cantali +3 more
wiley +1 more source
Genetic susceptibility and HLA association in autoimmune hepatitis among Yemeni patients. [PDF]
Farie WQ +5 more
europepmc +1 more source
From hepatic to hematopoietic: LRH‐1's expanding cellular repertoire to the immune system
The nuclear receptor LRH‐1 is a well‐characterized regulator of endodermal tissue. Yet, increasing evidence indicates that LRH‐1, although expressed at low levels, is also a critical regulator of the hematopoietic system. LRH‐1 regulates the immune system by contributing to immune cell‐specific functions.
Lukas Meisinger +3 more
wiley +1 more source
Autoimmune Hepatitis Following COVID-19 Vaccination in a Patient With Ulcerative Colitis: A Case Report. [PDF]
Algodi M +6 more
europepmc +1 more source
RNA and DNA viruses can manipulate host cell death through various mechanisms. RNA viruses (H1N1, SARS‐CoV‐2) induce acute apoptosis, necroptosis, and pyroptosis to promote rapid viral transmission and epithelial barrier damage. In contrast, DNA viruses (HSV‐1, EBV) regulate these mechanisms to sustain a lytic‐latency cycle, evade immune response and ...
Panagiotis Keramidas +4 more
wiley +1 more source
Cleavage-Resistant CYLD Protects Against Autoimmune Hepatitis. [PDF]
Liu H +13 more
europepmc +1 more source
Italian Patients Journey for Gene Therapy in Haemophilia A
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno +19 more
wiley +1 more source

